Purpose: e purpose of this study was to characterize the management and outcomes of patients with acromegaly seen in single center in Vancouver, British Columbia, Canada over a 30 year period.
Acromegaly is the result of prolonged growth hormone (GH) hypersecretion, and consequently raised insulin-like growth factor 1 (IGF-1) [1] . e cause is, most commonly, an autonomously functioning pituitary adenoma secreting GH or GH in combination with prolactin (PRL) or, very rarely, thyroid stimulating hormone (TSH) or adrenocorticotrophin hormone (ACTH). Extra-pituitary causes, including hypothalamic or ectopic growth hormone releasing hormone (GHRH) hypersecretion and ectopic pituitary adenomas secreting GH have also been reported [2, 3] . McCune-Albright syndrome, multiple endocrine neoplasia type 1 (MEN1) and Carney complex are genetic syndromes associated with acromegaly and, with familial acromegaly, have been recently reviewed [4] .
With an incidence of 3-4 per million per year and prevalence of 60 per million, acromegaly is a rare disease [1] . A recent study, based on raised IGF-1 levels, suggests underdiagnosis of acromegaly and, thus, a higher prevalence of 1034 per million [5, 6] . Acromegaly remains associated with signicant morbidity and mortality and, le untreated, patients die from a range of systemic complications 10 years younger than their healthy counterparts [6, 7] . e low incidence of the disease has prompted the initiation of several registries in Europe and the generation of valuable epidemiological data; however, similar studies have not been reported in North America [8] [9] [10] [11] . Here, we set out to analyse the management and outcomes of patients with acromegaly in a single tertiary center, in Vancouver, British Columbia (BC), Canada over the last 30 years, and to characterize the demography and epidemiology of acromegaly, the presence of co-morbidities and the e ectiveness of treatments used.
Materials and Methods

Patient Selection
Patients with a diagnosis of acromegaly 1980-2008, based on clinical records, were included in the study. e Division of Neurosurgery and the Department of Pathology at Vancouver General Hospital were involved in the diagnosis and management of majority of patients. Information was extracted from clinical and laboratory databases. A survey of all licenced endocrinologists in BC identi ed additional cases.
e crossreferencing between databases was accomplished using only patients' personal health number to ensure patient con dentiality. Each patient was assigned a unique code for use in the study database, which included no other identi able data. e Committee for Research and Ethical Behavior at UBC (CREB) approved the study. (Table 1) .
Data Collection
e following data were collected from medical records: demographic features, date of diagnosis, place of presentation (emergency, general practice, internal medicine, other specialist), presenting symptoms, tumor size and extension, pathology, visual elds, hormonal data (initial or follow-up GH, IGF-I concentration). Details on treatment were also collected: medical treatment, including current or previous and whether it was primary therapy, type and periods of medical treatment, radiotherapy treatment, including date, method and dose, number and route of surgical treatment(s) and co-morbidity related to the disease itself or to the treatment (gallstones, obstructive sleep apnea, visual defects, goiter, headache, hypopituitarism, diabetes mellitus, carpal tunnel syndrome, hypertension and neoplasms). No detailed information for mortality was available for this study.
Outcome Analysis: De nitions
Regarding the e ectiveness of treatment, the 'Criteria For Cure' was utilized as described in a consensus statement and the treatment outcomes based on a previous study [11, 12] . "Cure" is de ned as patients with previous surgery and/or radiotherapy and with both normalised IGF-1, as indicated by the individual lab reference range standardised for age and gender, and GH < 2 μg/l as indicated by their latest blood results. 'Controlled' uses the same criteria but for patients who were on primary medical therapy only (no surgery or radiotherapy). 'Active Disease' represented those patients with raised IGF-1 and GH ≥ 2 μg/l. Discordant GH and IGF-1 levels were also recorded, where present. It should also be noted that the GH and IGF-I assays have changed over time and results were presented based upon normal ranges used at the time of sample collection. 
Results
Population and prevalence
A total of 130 patient's charts were reviewed, of which 48.5% (63) were male and 51.5% (67) female, with mean ages at diagnosis of 43 years and 47 years, respectively. e prevalence was 29 per million, based upon BC statistical data from 2007.
Clinical presentation location
When clearly documented, the medical setting where the patient presented was recorded: 30.8% (40) presented to their general practitioner; 3.1% (4) presented to Emergency; 3.1% (4) presented to an endocrinologist; 3.1% (4) in Internal Medicine; and, 60% (78) were unknown. Other specialists who suggested a diagnosis of acromegaly, with presenting diagnoses in brackets, were neurologists (carpal tunnel); opticians and ophthalmologists (visual acuity and visual eld defects), orthopedic surgeries and rheumatologists (arthritis), endocrinologists (Facial characteristics), ENT specialists (snoring) and psychiatrists (depression and incidental MRI ndings). Table 2 lists the range of presenting symptoms recorded from the original patients' consultations, which were either the primary complaint(s), or elicited upon direct questioning.
Presenting Symptoms
Tumor Etiology and Pathology
All cases in this study were secondary to pituitary adenomas: 58.5% (76) were macroadenomas; 23.1% (30) were microadenomas; and, 18.5% (24) were unknown. e size, invasiveness and pathology were recorded from radiology and pathology reports, or where speci cally recorded in patients' records. Of the macroadenomas, 47.1% (36) were invasive and of the microadenomas, 13.3% (4) were invasive. With respect to tumor etiology, 19.2% (25) were pure GH, 18.5% (24) were GHprolactin secreting and 7.7% (10) were other mixed tumors, while 54.6% (71) were unknown.
Co-morbidities
e prevalence of co-morbidities, as reported in patients' charts, whether presenting before or a er diagnosis, is shown in Table 3 . Fi een patients were followed up for neoplasia, including breast (1), colon (1), haematological (4), thyroid (5), rectal (1), malignant melanoma (1), bladder (1) and prostate (1) . Patients with diabetes and arthropathy were, on average, 6 and 7 years older, respectively, than those without. Of the pa- (14) of the cases it is not known which methods were used. Medical treatment was used for the majority of patients 66.9% (87) at some time, mostly as adjunctive to surgery. Of these, 73.6% had been treated with somatostatin analogues (SSA) alone and 26.4% with both dopamine agonists (DA) and SSA, either sequentially or in combination. Two patients were treated with the GH receptor antagonist (GHRA), pegvisomant.
e cure rate for surgery or radiotherapy was 13.1% (17) . e majority 66.9% (87) of patients was not cured a er surgery, but good control of symptoms was reported with medical therapy for 22.3% of the patients (Table 4) .
Discussion
In this retrospective study, data contributed by 15 endocrinologists currently practicing in BC was analysed and 130 patients diagnosed with acromegaly since 1980 were identi ed.
e majority of cases, 67%, were from St. Paul's Hospital and Vancouver General Hospital, where most pituitary tumors in BC were managed. Based on these data, the prevalence of acromegaly in BC is 29 per 1,000,000. is estimate is less than the prevalence previously described [6, 11] , and could be due non-recognition of some cases, or to patients being referred from out of province. e suggested diagnosis of acromegaly was provided by a spectrum of medical specialties with 30.8% of known referrals from primary care. Due to the range of presenting complaints and complications associated with acromegaly spanning numerous specialties, it is a di erential diagnosis that physicians outside of endocrinology should be aware of. is is of particular importance in light of its insidious onset and the recent suggestion of sub-clinical, under-diagnosed GH-producing pituitary tumors [5] .
e mean age at diagnosis was 43 years (male) and 47 years (female) and did not di er from that reported in the other studies [10, 11, 13, 14] . ere was slight female preponderance (67 female), which is similar to what reported in Spanish Acromegaly Registry (n=1219 patients; 60.8% women) [10] and in the West Midlands Acromegaly database (n=419 patients; 57.5% women) [15] . In contrast, a slight male preponderance was reported by Beauregard et al. (58% men) [16] and no difference reported in the Belgian registry on acromegaly (418 patients: 51% men) [11] .
Acromegaly is di cult to diagnose. e most common presenting symptoms (acral enlargement; coarsening facial features/prognathism; sweating/oily skin'; headache; paraesthesia/numbness) can be easily overlooked by the patient or attributable to other common etiologies. Acne as a presenting feature of acromegaly is rarely included in reviews; however, the pathogenesis of increased sebum production is a commonly recognized feature of acromegaly. Case reports and comments on the association between acne and acromegaly have been made and in our study eight patients presented with acne [17] . All patients who presented with acne in this survey were female, with an average age of 37 years. Four patients presented with sweating/oily skin and one other presented with a concomitant menstrual disturbance. is association may be explained by the unusual presentation of acromegaly in younger women with features of polycystic ovarian syndrome or interference with LH/FSH secretion [18] (Table 5) .
is study addressed the extent to which acromegaly was complicated by co-morbidity, which was recorded in medical records, if noted. As the onset of acromegaly is insidious: patients can have unrecognized GH over-secretion and can accumulate morbidity over time. Like the Belgian Acromegaly Survey [11] , arthropathy, hypertension, diabetes mellitus and sleep apnea were the most commonly found morbidities; however, this study found signi cantly lower prevalence of cardiovascular disease, goiter, colonic polyps and visual eld defects.
is could be attributed to under-reporting, as data was not obtained via direct questioning of patients but were extracted from medical records. What is clear from both studies is the multi-disciplinary nature of managing patients with acromegaly and the necessity for regular review not only of GH and IGF-1 levels but also of the investigations carried out by other specialties. e sleep apnea syndrome was observed in 21.5% of our registry; however greater prevalence has been reported in other studies [19, 20] . is could be due to both a low awareness of the problem and to under-reporting by many physicians.
Colonic polyps were present in 8.5% of patients. Other reports on di erent populations recorded a prevalence of between 9.5% and 45% [10, 11, 21, 22] . is range of value is probably due to underutilization of colonoscopy or to underreporting.
e prevalence of gallstones in our registry was 6.2%. is is much lower than the prevalence observed in Belgian registry and Spanish database (23.4% and 9.5%, respectively) [10, 11] . Further awareness of this problem is required, especially with increased use of somatostatin analogues -where treatment results in the development of asymptomatic gallstones in up to 30% of patients [20] .
Surgery was the cornerstone of management for most patients (88.5%). Of the surgical patients, 21.5% went on to radiotherapy and 66.9% were subsequently treated medically.
ere was a marked reduction in the use of adjunctive radiotherapy a er 1999, which could be, in part, due to the availability of somatostatin therapy as adjuvant therapy for incomplete surgical cure. Surgery was associated with complications in 26.3% of cases, including cerebrospinal uid (CSF) leak (12.5%), temporary diabetes insipidus (10.0%), bleeding (3.8%) and SIADH (1.3%). Hypopituitarism was associated in 18.5 % of patients undergoing radiotherapy.
It has also been observed, over the last decade, that the use of somatostatin analogs has increased; however, there are no randomized controlled studies that compare primary medical therapy with initial surgery. Somatostatin analogs may be equally e ective if used as adjuvant or initial therapy [23, 24] and can be a good primary treatment option in carefully selected patients [24] [25] [26] . Among the active patients, two patients were on pegvisomant, with subsequent good control. Cost was a major barrier to use of this medication.
Stringent criteria were used to determine if a patient was cured based on their latest GH and IGF-1 results. Cure, a er only surgery and/or radiotherapy, or control, on medical treatment, required GH<2 μg/l and IGF-1 within normal limits. is is based on a consensus statement with a view to reducing mortality from acromegaly [27, 28] . Cure or control based on either GH or IGF-1 was found in 35.4% of patients while 30% still showed active disease.
ese results are probably closer to the outcomes encountered in clinical practice. In the Belgian registry, the cure or control rate was 49% [11] while in the Spanish database, cure was reported in 35% [10] . In accordance with previous reports, Biermasz et al. found 37% control rate 10 years a er transsphenoidal microsurgery [29] . In the current study, results were unobtainable for some patients. ere were a number of reasons for this: letters of referral were not included in patient's records; referral for followup with a detailed previous history were not included; or pathology reports were not included. Nevertheless, the majority of records were well kept and the relevant information easily extracted. Our registry of patients with acromegaly in Vancouver shows a relatively low cure rate following surgery but better results in controlling disease with medical treatment.
Patients tend to accumulate complications as time progresses, and further analysis of how patient morbidity relates to biochemical results will be important for managing and investigating patients within a multidisciplinary setting as well as in the endocrine clinic.
Our registry is small when compared to those of larger European countries. e lack of availability of centralized GH and IGF-I measurements, allowing a standardized evaluation of the outcome of di erent treatment strategies, also limits analysis. To improve GH and IGF-I measurements, the Acromegaly Consensus Group recommended that the World Health Organization (WHO) adopt international standards and the expression of GH results in mass units (micrograms per liter). Additionally, they address other issues with IGF-1 measurement, such as use of highly speci c antibodies and the need to establish normative data [30] . Mortality data, which was not available, would also strengthen our assessment of di erent treatment outcomes; however, it should be highlighted that untreated acromegaly is associated with reduced life expectancy, with 2-to 3-fold increased mortality in acromegalic patients compared with the general population [31] . In a recent meta-analysis of 16 studies, the weighted mean of the SMR of 1.72 (95% CI, 1.62-1.83) that, re ects a 72% increase in mortality in patients with acromegaly [32] . Successful treatment to reduce GH level to < 2-2.5 g/liter can reduce the mortality associated with acromegaly [31] .
Results of this study indicate that disease 'cure or control, based on either measurements of either GH or IGF-1, was found in 35.4% patients, whereas 30% still showed active disease. Cure rate was low following surgery but symptoms were at least partially controlled with adjuvant medical treatment. Our survey illustrates the changing pattern of therapy over the last decades in newly diagnosed acromegalic patients, with less reliance on radiotherapy and increased use of medical therapy.
